196 related articles for article (PubMed ID: 26993372)
1. Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study.
Worley MJ; Swanson A-N; Heinzerling KG; Roche DJ; Shoptaw S
Drug Alcohol Depend; 2016 May; 162():245-50. PubMed ID: 26993372
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder.
Heinzerling KG; Briones M; Thames AD; Hinkin CH; Zhu T; Wu YN; Shoptaw SJ
J Neuroimmune Pharmacol; 2020 Jun; 15(2):238-248. PubMed ID: 31820289
[TBL] [Abstract][Full Text] [Related]
3. The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study.
Ray LA; Bujarski S; Courtney KE; Moallem NR; Lunny K; Roche D; Leventhal AM; Shoptaw S; Heinzerling K; London ED; Miotto K
Neuropsychopharmacology; 2015 Sep; 40(10):2347-56. PubMed ID: 25801501
[TBL] [Abstract][Full Text] [Related]
4. Safety of Intravenous Methamphetamine Administration During Ibudilast Treatment.
DeYoung DZ; Heinzerling KG; Swanson AN; Tsuang J; Furst BA; Yi Y; Wu YN; Moody DE; Andrenyak DM; Shoptaw SJ
J Clin Psychopharmacol; 2016 Aug; 36(4):347-54. PubMed ID: 27269956
[TBL] [Abstract][Full Text] [Related]
5. Ibudilast attenuates peripheral inflammatory effects of methamphetamine in patients with methamphetamine use disorder.
Li MJ; Briones MS; Heinzerling KG; Kalmin MM; Shoptaw SJ
Drug Alcohol Depend; 2020 Jan; 206():107776. PubMed ID: 31812878
[TBL] [Abstract][Full Text] [Related]
6. Glial Attenuation With Ibudilast in the Treatment of Medication Overuse Headache: A Double-Blind, Randomized, Placebo-Controlled Pilot Trial of Efficacy and Safety.
Johnson JL; Kwok YH; Sumracki NM; Swift JE; Hutchinson MR; Johnson K; Williams DB; Tuke J; Rolan PE
Headache; 2015 Oct; 55(9):1192-208. PubMed ID: 26367865
[TBL] [Abstract][Full Text] [Related]
7. Gender differences in the behavioral and subjective effects of methamphetamine in healthy humans.
Mayo LM; Paul E; DeArcangelis J; Van Hedger K; de Wit H
Psychopharmacology (Berl); 2019 Aug; 236(8):2413-2423. PubMed ID: 31165207
[TBL] [Abstract][Full Text] [Related]
8. The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers.
De La Garza R; Mahoney JJ; Culbertson C; Shoptaw S; Newton TF
Pharmacol Biochem Behav; 2008 Apr; 89(2):200-8. PubMed ID: 18207225
[TBL] [Abstract][Full Text] [Related]
9. Ibudilast may improve attention during early abstinence from methamphetamine.
Birath JB; Briones M; Amaya S; Shoptaw S; Swanson AN; Tsuang J; Furst B; Heinzerling K; Obermeit L; Maes L; McKay C; Wright MJ
Drug Alcohol Depend; 2017 Sep; 178():386-390. PubMed ID: 28704767
[TBL] [Abstract][Full Text] [Related]
10. Rivastigmine reduces "Likely to use methamphetamine" in methamphetamine-dependent volunteers.
De La Garza R; Newton TF; Haile CN; Yoon JH; Nerumalla CS; Mahoney JJ; Aziziyeh A
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Apr; 37(1):141-6. PubMed ID: 22230648
[TBL] [Abstract][Full Text] [Related]
11. Glial cell modulators attenuate methamphetamine self-administration in the rat.
Snider SE; Hendrick ES; Beardsley PM
Eur J Pharmacol; 2013 Feb; 701(1-3):124-30. PubMed ID: 23375937
[TBL] [Abstract][Full Text] [Related]
12. Ibudilast reverses the decrease in the synaptic signaling protein phosphatidylethanolamine-binding protein 1 (PEBP1) produced by chronic methamphetamine intake in rats.
Charntikov S; Pittenger ST; Thapa I; Bastola DR; Bevins RA; Pendyala G
Drug Alcohol Depend; 2015 Jul; 152():15-23. PubMed ID: 25962787
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers.
De La Garza R; Zorick T; London ED; Newton TF
Drug Alcohol Depend; 2010 Jan; 106(2-3):173-80. PubMed ID: 19781865
[TBL] [Abstract][Full Text] [Related]
14. Isradipine, a dihydropyridine-class calcium channel antagonist, attenuates some of d-methamphetamine's positive subjective effects: a preliminary study.
Johnson BA; Roache JD; Bordnick PS; Ait-Daoud N
Psychopharmacology (Berl); 1999 Jun; 144(3):295-300. PubMed ID: 10435398
[TBL] [Abstract][Full Text] [Related]
15. Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence.
Metz VE; Jones JD; Manubay J; Sullivan MA; Mogali S; Segoshi A; Madera G; Johnson KW; Comer SD
Neuropsychopharmacology; 2017 Aug; 42(9):1825-1832. PubMed ID: 28393896
[TBL] [Abstract][Full Text] [Related]
16. Buspirone maintenance does not alter the reinforcing, subjective, and cardiovascular effects of intranasal methamphetamine.
Reynolds AR; Strickland JC; Stoops WW; Lile JA; Rush CR
Drug Alcohol Depend; 2017 Dec; 181():25-29. PubMed ID: 29028556
[TBL] [Abstract][Full Text] [Related]
17. Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial.
Anderson AL; Li SH; Markova D; Holmes TH; Chiang N; Kahn R; Campbell J; Dickerson DL; Galloway GP; Haning W; Roache JD; Stock C; Elkashef AM
Drug Alcohol Depend; 2015 May; 150():170-4. PubMed ID: 25818061
[TBL] [Abstract][Full Text] [Related]
18. Ibudilast attenuates alcohol cue-elicited frontostriatal functional connectivity in alcohol use disorder.
Burnette EM; Ray LA; Irwin MR; Grodin EN
Alcohol Clin Exp Res; 2021 Oct; 45(10):2017-2028. PubMed ID: 34585396
[TBL] [Abstract][Full Text] [Related]
19. The glial cell modulators, ibudilast and its amino analog, AV1013, attenuate methamphetamine locomotor activity and its sensitization in mice.
Snider SE; Vunck SA; van den Oord EJ; Adkins DE; McClay JL; Beardsley PM
Eur J Pharmacol; 2012 Mar; 679(1-3):75-80. PubMed ID: 22306241
[TBL] [Abstract][Full Text] [Related]
20. Effects of moderate- and high-intensity acute aerobic exercise on food reward and appetite in individuals with methamphetamine dependence.
Zhou Y; Lu Y; Jin X; Liu J; Finlayson G; Zhou C
Physiol Behav; 2019 Nov; 211():112649. PubMed ID: 31419449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
